Zacks Investment Research
04 Jun 2026, 15:46 UTC · 1h ago
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
Search tags
Zacks Investment Research
04 Jun 2026, 15:46 UTC · 1h ago
Search tags
Story key points
3 claims · impact-rated
ADC Therapeutics shares plunged 53.4% in after-hours trading following results from the LOTIS-5 study. — A massive share price collapse reflects a severe loss of investor confidence in the company's valuation and future.
-1.00Investors focused on safety findings in the LOTIS-5 study showing higher rates of serious adverse events, treatment discontinuations, and fatal adverse events in the Zynlonta experimental arm. — Safety concerns and fatalities in a late-stage trial create significant regulatory risk and limit the potential commercial viability of the drug.
-0.80The phase III LOTIS-5 study met its primary efficacy endpoint, showing a median progression-free survival of 6.1 months for Zynlonta plus Rituxan versus 4.7 months for the control group. — Positive efficacy data is generally bullish, but in this case, it was heavily outweighed by the safety concerns.
+0.30Ticker attribution
Continue reading
6 related stories
Model heads
Shares plunged over 50% due to safety concerns and fatal adverse events in a clinical study.
Mentioned as a partner in a study, but the primary market reaction was focused on ADCT's safety data.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
3 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
Seeking Alpha
45m ago
